FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling


Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Aim(s): The main objective is to compare the progression-free survival with mFOLFIRINOX regimen versus PE. The secondary objectives are to evaluate objective response rates according to RECIST 1.1, overall survival, safety and quality of life. A molecular profile with targeted NGS and immunohistochemistry will be performed for all patients with tumor available. Rb expression/mutation, will be studied as a predictive biomarker of response.

Materials and methods: The main inclusion criteria will be: NEC of GEP or unknown origin, metastatic and evaluable disease and no contraindication to chemotherapy. Patients will be randomized 1:1 between PE every 21 days for up to 8 cycles and mFOLFIRINOX every 14 days (5FU 2400 mg/m², irinotecan 180 mg/m², oxaliplatin 85 mg/m²) for up to 12 cycles and stratified according to center, PS, Ki67 and pathological subtype (small vs large cell or undetermined).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

To read the full abstract, please log into your ENETS Member account.